┌──────────────────────────────────────────────────────────────┐ RECORD TYPE ......... SUBJECT FILE SUBJECT TYPE ........ ORG FILE OPENED ......... 2026-07-05 17:23 UTC APPEARANCES ......... 10 ANNOTATIONS KNOWN ALIASES ....... 1 └──────────────────────────────────────────────────────────────┘
SmithKline Beecham
ALSO APPEARS AS
- SmithKline Beecham
APPEARS IN THE MARGINS OF
- Paroxetine Prescriptions for Adolescents (2001-2015) After Study 329 Publication
Study 329 was a clinical trial of paroxetine and imipramine in adolescents with major depression, funded by SmithKline Beecham and published in 2001. The original publication by Keller and colleagues …
- GSK Contractual Restrictions on Paroxetine Research Publication
This investigation concerns whether GlaxoSmithKline (GSK) contractually restricted Martin Keller's ability to publish findings unfavorable to the antidepressant paroxetine (marketed as Paxil/Seroxat),…
- SmithKline Beecham Study 329 Adverse Event Data Submission to FDA
Study 329 was a clinical trial of paroxetine (Paxil) in adolescents with major depressive disorder, conducted by SmithKline Beecham (now GlaxoSmithKline - GSK). The original published report in 2001 p…
- Study 329: Contents of Appendix H and GSK's Data Provision to RIAT
Study 329 was a clinical trial sponsored by SmithKline Beecham (now GSK) investigating paroxetine in adolescents with depression. The original published results by Keller et al. in 2001 were subsequen…
- Martin Keller's Role and Statements in Study 329 Paroxetine Trial
Study 329 was a clinical trial conducted from 1994 to 1998 to evaluate the efficacy of paroxetine (Paxil/Seroxat), an SSRI antidepressant, for major depressive disorder in adolescents aged 12-18 [2, 6…
- FDA Internal Review of Study 329 Adverse Events Pre-RIAT
Study 329 was a clinical trial conducted by SmithKline Beecham (now GlaxoSmithKline) between 1994 and 1998, investigating the efficacy and safety of paroxetine and imipramine in adolescents with major…
- Medical Guidance on Paroxetine for Adolescents and Study 329 Reference (2001-2015)
Following the 2001 publication of Study 329, an influential clinical trial on the antidepressant paroxetine (Paxil/Seroxat) for adolescent depression, questions arose regarding its efficacy and safety…
- GlaxoSmithKline Study 329: Ghostwriting and Non-Disclosure Claims
Study 329 was a clinical trial of the antidepressant Paxil (paroxetine) conducted by SmithKline Beecham (now GlaxoSmithKline) between 1994 and 1998, comparing it to Tofranil and placebo in depressed c…
- Journal of the American Academy of Child and Adolescent Psychiatry Pre-2015 Ghostwriting Policies
This dossier investigates whether the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP), the original publisher of Study 329, had explicit editorial policies or communication…
- Study 329: Allegations of Ghostwriting in Paroxetine Clinical Trial
Study 329 was a clinical trial conducted by SmithKline Beecham (now GlaxoSmithKline or GSK) between 1994 and 1998 to evaluate the efficacy of paroxetine (Paxil) in adolescents with major depressive di…